Skip to main content
. 2022 Apr 25;198(1):82–92. doi: 10.1111/bjh.18183

FIGURE 1.

FIGURE 1

Response to BEGEV: (A) pre‐Nivolumab: persistence of pathological uptake at the left latero‐cervical level, at the hepatic hilum, and in proximity of right iliac vessels. New lesions at the left superior paratracheal level, at the splenic hilum, para‐cavally. Two new bone lesions in two dorsal vertebral bodies; persistence of bone lesions in the left pelvis. Deauville score (DS) 5; (B) post‐Nivolumab. Complete regression of previous areas of uptake. DS3